^
Association details:
| Biomarker: | IDH2 mutation + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy
Published date:
01/05/2021
Excerpt:
A 55-year-old man was diagnosed with CML. He achieved a complete cytogenetic response three months after dasatinib therapy but developed AML with normal karyotype 1 year late...After receiving induction and consolidation chemotherapy for AML, the patient achieved complete remission with no evidence of CML under maintenance with bosutinib. Targeted sequencing of serial bone marrow samples identified mutations in IDH2 and NPM1 in the Ph-negative AML cells...
DOI:
10.1007/s12185-020-03074-7
